Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dendritic cell counts and their subsets during treatment of multiple myeloma

L Kovarova, T Buchler, L Pour, L Zahradova, D Ocadlikova, A Svobodnik, M Penka, J Vorlicek, R Hajek

. 2007 ; 54 (4) : 297-303.

Jazyk angličtina Země Slovensko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10015038

Grantová podpora
NR8081 MZ0 CEP - Centrální evidence projektů

Human dendritic cells have distinct roles in the regulation of immunity. In this study we analysed the kinetics and the proportion of myeloid and plasmacytoid subsets of dendritic cells (DC) in peripheral blood of 15 patients with multiple myeloma (MM) before and during treatment that included autologous transplantation. Control group of 15 healthy volunteers was evaluated by using the same approaches. Flowcytometric determination of relative and absolute cell counts in unmanipulated peripheral blood was based on the expression of surface antigens CD83 and HLA-DR. Depending on the expression of CD11c or CD123, we divided these cells into CD11c+ dendritic cells type 1 (DC1) and CD123+ DC type 2 (DC2). Significant differences were found in initial relative counts of CD83+ cells and of the DC2 subtype between the group of controls and the group of patients before treatment. In absolute counts, there was a difference only in the DC2 subtype. After induction treatment (vincristine, doxorubicin, and dexamethasone), the mean percentage of CD83+ DC and the DC1 percentage were significantly higher than initially, but there was no significant difference in absolute counts. Administration of G-CSF again increased the total DC numbers. Intermediate DC counts were found in the apheresis products. After engraftment, we found the highest relative DC numbers, but absolute counts were not very high because of leukopenia. Within six months after transplantation, normal relative and absolute DC counts were found in patients. Untreated patients with MM have significantly lower relative numbers of peripheral blood DC in comparison with healthy volunteers. The highest number of total DC was found after engraftment. The DC1/DC2 ratio showed relative predominance of DC1 subtype and the lowest DC1/DC2 ratio was found in the apheresis products. DC counts comparable with those of healthy volunteers were found in patients six months after transplantation.

000      
04381naa 2200625 a 4500
001      
bmc10015038
003      
CZ-PrNML
005      
20130923162846.0
008      
100623s2007 xo e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Říhová, Lucie $7 xx0081970
245    10
$a Dendritic cell counts and their subsets during treatment of multiple myeloma / $c L Kovarova, T Buchler, L Pour, L Zahradova, D Ocadlikova, A Svobodnik, M Penka, J Vorlicek, R Hajek
314    __
$a Laboratory of Experimental Hematology and Immunotherapy, Department of Clinical Hematology, University Hospital, Czech Republic lkovarova@fnbrno.cz
520    9_
$a Human dendritic cells have distinct roles in the regulation of immunity. In this study we analysed the kinetics and the proportion of myeloid and plasmacytoid subsets of dendritic cells (DC) in peripheral blood of 15 patients with multiple myeloma (MM) before and during treatment that included autologous transplantation. Control group of 15 healthy volunteers was evaluated by using the same approaches. Flowcytometric determination of relative and absolute cell counts in unmanipulated peripheral blood was based on the expression of surface antigens CD83 and HLA-DR. Depending on the expression of CD11c or CD123, we divided these cells into CD11c+ dendritic cells type 1 (DC1) and CD123+ DC type 2 (DC2). Significant differences were found in initial relative counts of CD83+ cells and of the DC2 subtype between the group of controls and the group of patients before treatment. In absolute counts, there was a difference only in the DC2 subtype. After induction treatment (vincristine, doxorubicin, and dexamethasone), the mean percentage of CD83+ DC and the DC1 percentage were significantly higher than initially, but there was no significant difference in absolute counts. Administration of G-CSF again increased the total DC numbers. Intermediate DC counts were found in the apheresis products. After engraftment, we found the highest relative DC numbers, but absolute counts were not very high because of leukopenia. Within six months after transplantation, normal relative and absolute DC counts were found in patients. Untreated patients with MM have significantly lower relative numbers of peripheral blood DC in comparison with healthy volunteers. The highest number of total DC was found after engraftment. The DC1/DC2 ratio showed relative predominance of DC1 subtype and the lowest DC1/DC2 ratio was found in the apheresis products. DC counts comparable with those of healthy volunteers were found in patients six months after transplantation.
650    _2
$a CD antigeny $x metabolismus $7 D015703
650    _2
$a antigeny CD11c $x metabolismus $7 D039521
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a počet buněk $7 D002452
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a dendritické buňky $x cytologie $x klasifikace $7 D003713
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a faktor stimulující kolonie granulocytů $x aplikace a dávkování $7 D016179
650    _2
$a HLA-DR antigeny $x metabolismus $7 D006684
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny $x metabolismus $7 D007136
650    _2
$a receptor interleukinu-3 - alfa-podjednotka $x metabolismus $7 D053650
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové glykoproteiny $x metabolismus $7 D008562
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x imunologie $x metabolismus $x terapie $7 D009101
650    _2
$a transplantace periferních kmenových buněk $7 D036102
650    _2
$a indukce remise $7 D012074
650    _2
$a časové faktory $7 D013997
650    _2
$a autologní transplantace $7 D014182
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
650    _2
$a financování organizované $7 D005381
700    1_
$a Büchler, Tomáš, $7 xx0096851 $d 1974-
700    1_
$a Pour, Luděk $7 xx0102556
700    1_
$a Szeligová, Lenka $7 xx0098951
700    1_
$a Očadlíková, Darina. $7 xx0181164
700    1_
$a Svobodník, Adam, $d 1975- $7 xx0026812
700    1_
$a Penka, Miroslav, $d 1952- $7 nlk19990073680
700    1_
$a Vorlíček, Jiří, $d 1944- $7 jn20000402598
700    1_
$a Hájek, Roman, $d 1964- $7 nlk20000083645
773    0_
$t Neoplasma $w MED00003470 $g Roč. 54, č. 4 (2007), s. 297-303 $x 0028-2685
910    __
$a ABA008 $b A 1194 $y 8
990    __
$a 20100630115239 $b ABA008
991    __
$a 20130923163356 $b ABA008
999    __
$a ok $b bmc $g 750906 $s 614584
BAS    __
$a 3
BMC    __
$a 2007 $b 54 $c 4 $d 297-303 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
GRA    __
$a NR8081 $p MZ0
LZP    __
$a 2010-B1/mkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...